PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Highlights the firm's ability to meet near-term obligations and cover interest expenses. For conservative value investors, strong liquidity and coverage metrics are critical to avoid distress or forced dilution.
5.52
0.5–0.75x CRVO's 10.03. Martin Whitman would question if short-term obligations are sufficiently covered.
5.52
0.5–0.75x CRVO's 10.03. Martin Whitman might be concerned about coverage if a crisis hits.
5.34
0.5–0.75x CRVO's 9.18. Martin Whitman would question if short-term obligations are too high relative to cash.
-1373.41
Negative interest coverage while CRVO shows 0.00. Joel Greenblatt would look for earnings improvements and debt restructuring catalysts.
-30.63
Negative short-term coverage while CRVO shows 0.00. Joel Greenblatt would look for cash flow improvements and refinancing catalysts.